Navigation Links
Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease
Date:12/7/2007

inically tested in more than 5,200 patients globally, with nearly 1,000 of these patients having been followed for more than one year. In addition, more than 87,000 patients have been prescribed FOSRENOL in the US alone. FOSRENOL has the most extensive long-term safety data package of any phosphate binder and is generally well tolerated. Trials involving patients treated with FOSRENOL showed sustained serum phosphorus reduction in a majority of patients, with some patients being followed over a six-year duration.

FOSRENOL is now available in 23 countries, including Canada, France, Germany, Italy, and the UK, and continues to be launched in new markets around the world.

Important Safety Information

The most common adverse events were gastrointestinal, such as nausea and vomiting, and generally abated over time with continued dosing. The most common side effects leading to discontinuation in clinical trials were gastrointestinal events (nausea, vomiting, and diarrhea). Other side effects reported in trials included dialysis graft complications, headache, abdominal pain, and hypotension. Although studies were not designed to detect differences in risk of fracture and mortality, there were no differences demonstrated in patients treated with FOSRENOL compared to alternative therapy for up to three years. The duration of treatment exposure and time of observation in the clinical program were too short to conclude that FOSRENOL does not affect the risk of fracture or mortality beyond three years. While lanthanum has been shown to accumulate in the GI tract, liver, and bone in animals, the clinical significance in humans is unknown. Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease, or bowel obstruction were not included in FOSRENOL clinical studies. Caution should be used in patients with these conditions. FOSRENOL should not be taken by patients who are nursing or pregnant. FOSRENOL should not be taken by patients who are under 18
'/>"/>

SOURCE Shire Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
2. The next generation: nanomagnets could replace semiconductors
3. IBM and Imago find a crucial difficulty in semiconductor device scaling
4. Doping technique brings nanomechanical devices into the semiconductor world
5. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
6. NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company
7. New Web Site Tools Help Alleviate Stress Associated with Caring for Children with Diabetes During the Holidays
8. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 2014 Pressure BioSciences, Inc. (OTCQB: PBIO) ... the development and sale of high pressure-based sample ... today announced that Professor Ruedi Aebersold ... reproducible, and robust method to allow – for ... on small needle biopsy samples by mass spectrometry ...
(Date:10/27/2014)... Investor-Edge has initiated coverage on ... NBIX ), Insmed Inc. (NASDAQ: INSM ), ... Corporation (NASDAQ: DYAX ), and Oncothyreon Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced ...
(Date:10/26/2014)... October 26, 2014 The report "Protective ... Application - Global Trends & Forecast to 2019", defines ... and forecasting of volume consumed and value generated. The ... KT in 2014 to 6,701.3 KT by 2019, at ... Browse 91 market data tables and 22 figures spread ...
(Date:10/25/2014)... October 23, 2014 ViaDerma, ... pharmaceutical company devoted to bringing new products to ... 2015. , ViaDerma has developed an innovative, patent-pending ... rapid mass transfer of pharmaceutical active ingredients to ... provide immediate localized therapy. The transdermal delivery method ...
Breaking Biology Technology:Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... DIEGO, June 14, 2011 OncoSec Medical Inc. ... therapies to treat solid tumor cancers, announced today ... lead the clinical operations of OncoSec,s ElectroOncology therapies. ... Punit Dhillon, OncoSec,s President and CEO, said, "OncoSec ...
... Fox Chase Cancer Center , one of ... announced it has entered into an agreement with Life ... provide next-generation sequencing analysis of solid tumors.  The agreement ... Institute at Fox Chase, a facility that will foster ...
... Dendreon Corporation (Nasdaq: DNDN ) today announced that ... the Ernst & Young Entrepreneur Of The Year ® ... category. Dr. Gold has served as CEO ... last year received U.S. Food and Drug Administration approval for ...
Cached Biology Technology:OncoSec Announces Clinical Leadership Appointments 2OncoSec Announces Clinical Leadership Appointments 3OncoSec Announces Clinical Leadership Appointments 4Fox Chase Cancer Center Signs Agreement with Life Technologies Corporation 2Fox Chase Cancer Center Signs Agreement with Life Technologies Corporation 3Fox Chase Cancer Center Signs Agreement with Life Technologies Corporation 4Fox Chase Cancer Center Signs Agreement with Life Technologies Corporation 5Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner 2Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner 3Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner 4Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner 5
(Date:10/29/2014)... is open for the Society of Interventional ... 2015 is the one place where interventional ... health care professionals can come together to ... technologies being presented, discussed and tested. ... invasive, image-guided medicine, SIR 2015 will feature ...
(Date:10/29/2014)... chemicals from household and industrial products are in the ... for most of them, scientists have yet to determine ... first step toward doing that by estimating which substances ... is published in the ACS journal Environmental Science ... note that the risks to human health of any ...
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2MSU partners with Detroit to investigate death scenes 2
... let the bedbugs bite" is becoming an impossible dream ... resurgence of an ancient scourge that is fostering human ... potentially toxic materials. That,s the message from the cover ... News (C&EN), ACS, weekly newsmagazine. In the article, ...
... world leading publisher of scientific information products and services, ... Environment, today formalized their collaboration to publish the new ... the final quarter of 2011. This publication, supported by ... to the dynamic and impressive expansion of both environmental ...
... whale season, researchers from Hawai,i Institute of Marine Biology ... shed new light on the wintering grounds of the ... Pacific was always thought to be the main Hawaiian ... these grounds extend all the way throughout the Hawaiian ...
Cached Biology News:SCOPE and Elsevier partner to publish Environmental Development 2Researchers discover new wintering grounds for humpback whales using sound 2
... The PinPoint™ Vector Sequencing Primer is ... PinPoint™ Xa Vectors (Cat.# V2031, V2051, V2061). ... Xa site at nucleotides 325343, approximately 4050 ... region and can be used to determine ...
Medium for cryopreserving subcutaneous or omental preadipocytes...
... ultra high yield technology is fast - ... aRNA for gene array analysis ... , Kits specific for templates with ... , All kits contain SUPERaseIn ...
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
Biology Products: